• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Protalix Biotherapeutics (NY: PLX )

    1.000 -0.020 (-1.96%)
    Official Closing Price Updated: 8:00 PM EDT, Sep 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 68,828
    Open 1.020
    Bid (Size) 0.9850 (1)
    Ask (Size) 1.070 (150)
    Prev. Close 1.020
    Today's Range 0.9935 - 1.030
    52wk Range 0.8214 - 1.900
    Shares Outstanding 73,542,674
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Beats Revenue for Q2 2024
    PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    -45.05%
    -45.05%
    1 Month
    N/A
    N/A
    3 Month
    -10.71%
    -10.71%
    6 Month
    -32.89%
    -32.89%
    1 Year
    -45.65%
    -45.65%

    More News

    Read More
    PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Pullix Gains Momentum As Gamestop Exits NFT Space
    Via Talk Markets
    Earnings Scheduled For November 6, 2023
    Via Benzinga
    Earnings Preview For Protalix BioTherapeutics
    Via Benzinga
    Preview: Protalix BioTherapeutics's Earnings
    Via Benzinga
    Protalix Clocks 40% Decline In Q1 Revenues Reflecting Lower Sales To Brazil
    Via Benzinga
    Earnings Scheduled For March 14, 2024
    Via Benzinga
    Earnings Preview: Protalix BioTherapeutics
    Via Benzinga
    Earnings Preview For Protalix BioTherapeutics
    Via Benzinga
    Looking Into Protalix BioTherapeutics's Return On Capital Employed
    Via Benzinga
    Protalix BioTherapeutics Well Placed to Advance in 2023
    Via Talk Markets
    Protalix BioTherapeutics And 2 Other Penny Stocks Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    Why Lucira Health Shares Are Trading Higher By Over 228%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    $12.5 Million Bet On Biodesix? Check Out These 4 Penny Stocks Insiders Are Buying
    Via Benzinga
    Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
    Via News Direct
    Exposures Product Safety
    Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
    Via TheNewswire.com
    Exposures Product Safety
    Earnings Scheduled For February 27, 2023
    Via Benzinga
    Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment
    Via Benzinga
    Earnings Scheduled For November 14, 2022
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.